Literature DB >> 18022567

Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth.

Galina I Lepesheva1, Robert D Ott, Tatiana Y Hargrove, Yuliya Y Kleshchenko, Inge Schuster, W David Nes, George C Hill, Fernando Villalta, Michael R Waterman.   

Abstract

Sterol 14alpha-demethylases (CYP51) serve as primary targets for antifungal drugs, and specific inhibition of CYP51s in protozoan parasites Trypanosoma brucei (TB) and Trypanosoma cruzi (TC) might provide an effective treatment strategy for human trypanosomiases. Primary inhibitor selection is based initially on the cytochrome P450 spectral response to ligand binding. Ligands that demonstrate strongest binding parameters were examined as inhibitors of reconstituted TB and TC CYP51 activity in vitro. Direct correlation between potency of the compounds as CYP51 inhibitors and their antiparasitic effect in TB and TC cells implies essential requirements for endogenous sterol production in both trypanosomes and suggests a lead structure with a defined region most promising for further modifications. The approach developed here can be used for further large-scale search for new CYP51 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022567      PMCID: PMC2324070          DOI: 10.1016/j.chembiol.2007.10.011

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  51 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  High-efficiency clonal growth of bloodstream- and insect-form Trypanosoma brucei on agarose plates.

Authors:  V B Carruthers; G A Cross
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

3.  Comparative genomics of trypanosomatid parasitic protozoa.

Authors:  Najib M El-Sayed; Peter J Myler; Gaëlle Blandin; Matthew Berriman; Jonathan Crabtree; Gautam Aggarwal; Elisabet Caler; Hubert Renauld; Elizabeth A Worthey; Christiane Hertz-Fowler; Elodie Ghedin; Christopher Peacock; Daniella C Bartholomeu; Brian J Haas; Anh-Nhi Tran; Jennifer R Wortman; U Cecilia M Alsmark; Samuel Angiuoli; Atashi Anupama; Jonathan Badger; Frederic Bringaud; Eithon Cadag; Jane M Carlton; Gustavo C Cerqueira; Todd Creasy; Arthur L Delcher; Appolinaire Djikeng; T Martin Embley; Christopher Hauser; Alasdair C Ivens; Sarah K Kummerfeld; Jose B Pereira-Leal; Daniel Nilsson; Jeremy Peterson; Steven L Salzberg; Joshua Shallom; Joana C Silva; Jaideep Sundaram; Scott Westenberger; Owen White; Sara E Melville; John E Donelson; Björn Andersson; Kenneth D Stuart; Neil Hall
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

4.  Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi.

Authors:  K Lazardi; J A Urbina; W de Souza
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Receptors for the host low density lipoproteins on the hemoflagellate Trypanosoma brucei: purification and involvement in the growth of the parasite.

Authors:  I Coppens; P Baudhuin; F R Opperdoes; P J Courtoy
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 6.  P450 inhibitors of use in medical treatment: focus on mechanisms of action.

Authors:  H Vanden Bossche; L Koymans; H Moereels
Journal:  Pharmacol Ther       Date:  1995       Impact factor: 12.310

7.  The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis.

Authors:  A Gebre-Hiwot; D Frommel
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

8.  Effects of an azasterol inhibitor of sterol 24-transmethylation on sterol biosynthesis and growth of Leishmania donovani promastigotes.

Authors:  P A Haughan; M L Chance; L J Goad
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

9.  Treatment of chronic Chagas' disease with itraconazole and allopurinol.

Authors:  W Apt; X Aguilera; A Arribada; C Pérez; C Miranda; G Sánchez; I Zulantay; P Cortés; J Rodriguez; D Juri
Journal:  Am J Trop Med Hyg       Date:  1998-07       Impact factor: 2.345

10.  Cure of short- and long-term experimental Chagas' disease using D0870.

Authors:  J A Urbina; G Payares; J Molina; C Sanoja; A Liendo; K Lazardi; M M Piras; R Piras; N Perez; P Wincker; J F Ryley
Journal:  Science       Date:  1996-08-16       Impact factor: 47.728

View more
  68 in total

1.  Structural insights into inhibition of sterol 14alpha-demethylase in the human pathogen Trypanosoma cruzi.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Spencer Anderson; Yuliya Kleshchenko; Vyacheslav Furtak; Zdzislaw Wawrzak; Fernando Villalta; Michael R Waterman
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 3.  Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51).

Authors:  Galina I Lepesheva; Fernando Villalta; Michael R Waterman
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

4.  Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

Authors:  Andrew G S Warrilow; Claire M Martel; Josie E Parker; Nadja Melo; David C Lamb; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

5.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

Authors:  Frederick S Buckner; Julio A Urbina
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-12       Impact factor: 4.077

6.  Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Paul W Alexander; Jason H Chaplin; Martine Keenan; Susan A Charman; Catherine J Perez; Michael R Waterman; Eric Chatelain; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

7.  Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

Authors:  Laura Friggeri; Tatiana Y Hargrove; Girish Rachakonda; Anna L Blobaum; Paxtyn Fisher; Gabriel Melo de Oliveira; Cristiane França da Silva; Maria de Nazaré C Soeiro; W David Nes; Craig W Lindsley; Fernando Villalta; F Peter Guengerich; Galina I Lepesheva
Journal:  J Med Chem       Date:  2018-11-30       Impact factor: 7.446

8.  Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.

Authors:  Grasiella Andriani; Emanuele Amata; Joel Beatty; Zeke Clements; Brian J Coffey; Gilles Courtemanche; William Devine; Jessey Erath; Cristin E Juda; Zdzislaw Wawrzak; Jodianne T Wood; Galina I Lepesheva; Ana Rodriguez; Michael P Pollastri
Journal:  J Med Chem       Date:  2013-03-13       Impact factor: 7.446

9.  A convergent, scalable and stereoselective synthesis of azole CYP51 inhibitors.

Authors:  Galina Lepesheva; Plamen Christov; Gary A Sulikowski; Kwangho Kim
Journal:  Tetrahedron Lett       Date:  2017-09-25       Impact factor: 2.415

10.  Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase.

Authors:  Mary E Konkle; Tatiana Y Hargrove; Yuliya Y Kleshchenko; Jens P von Kries; Whitney Ridenour; Md Jashim Uddin; Richard M Caprioli; Lawrence J Marnett; W David Nes; Fernando Villalta; Michael R Waterman; Galina I Lepesheva
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.